Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repotrectinib pharmacokinetics in hepatic impairment
NCT06352528Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of repotrectinib (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration, Time of Maximum Observed Plasma Concentration and 2 more. Started Apr 2024; status: completed.
02
Drugs
repotrectinib
Beyond the preview
Go deeper on NCT06352528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352528.